|
New Years Greetings
Dear LTI supporter,
On behalf of all of us at LTI, I wish you and your loved ones health and happiness in celebrating the holidays and throughout the new year. The prospects of 2024 hold promise of new challenges to address and goals to achieve. Here’s to a new year filled with possibilities, innovations, and continuing collaboration.
I am filled with gratitude for the hard work of my colleagues at LTI and our wonderful collaborators, partners, and supporters, all of whom have made critical contributions to our successes. This gratitude for the past year complements the past 31 years of collaborations and continuing growth. We have experienced extraordinary progress in our innovative technologies in supporting our clients in developing effective and globally accessible health solutions.
One example is our Development Sciences team, in collaboration with a prominent research institute, achieving significant progress in the global efforts to combat TB. Together they demonstrated a lyophilized presentation of an adjuvanted TB vaccine candidate is stable at 38°C for several months, and the vaccine is safe and induces strong immune responses.
Our clinical manufacturing and quality teams successfully implemented improvements to meet, and in some facets, exceed the requirements of the EU GMP Annex 1 revision prior to the August 2023 target. These improvements made it possible for us to turn LTI's innovative science into real world solutions in supporting our clients in bringing new products to patients in need throughout the world. Our manufacturing and quality teams employed these improvements for making clinical study materials and completed production runs of experimental drug products manufactured in our state-of-the-art cGMP aseptic processing operations.
LTI continues to advance our dual chamber delivery device with the support and collaboration of our many valued partners. They leverage our extensive formulation and device process expertise, coupled with their delivery device, to make next generation of delivery systems work better for self-administration in the home health care setting.
We cannot pursue our mission as a source of unique development services and as a research center without the support and enthusiasm of our community of clients and partners. We have exciting plans for 2024 and are deeply grateful for your continued support as we strive to make LTI’s unique technologies available as a leading source of development services and clinical trial material manufacturing.
Together, we can support supplying globally accessible products to address unmet medical needs as we work toward a world in which all are able to live healthy lives, free from illness and disease.
With great gratitude,
Edward H. Trappler
Edward H. Trappler
Founder and President
| 
